CordenPharma invests €900m in peptide patform expansion
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Catalym raises US$150m
German cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Sensorion achieves milestones in Phase II trial
French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
Rentschler doubles cGMP capacity
In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
SciRhom GmbH closes €63m Series A financing
German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
Ligand Pharma to acquire Apeiron Biologics
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
EuroscreenFast and GW Vitek announce distribution partnership in Korea
Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.
Anacura aquires Ohmx.bio
Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.